A 6-hour-old female neonate born at 39 weeks gestation to a 32-year-old multigravida with thick meconium-stained amniotic fluid (MSAF) presents with severe respiratory distress, grunting, nasal flaring, and cyanosis. She required intubation and mechanical ventilation. Chest X-ray shows diffuse bilateral infiltrates with hyperinflation and areas of atelectasis. Despite conventional mechanical ventilation (FiO₂ 0.8, PEEP 8 cm H₂O), her SpO₂ remains 82–85% and PaCO₂ is 68 mmHg. She develops acute pulmonary hypertension with tricuspid regurgitation on echocardiography. What is the most appropriate next step in management?

Explanation

## Management of Severe Meconium Aspiration Syndrome with Pulmonary Hypertension ### Clinical Scenario Analysis This neonate has **severe MAS with refractory hypoxemia and hypercarbia** despite optimal conventional mechanical ventilation. The presence of **pulmonary hypertension with tricuspid regurgitation** indicates severe disease with right-to-left shunting. ### Pathophysiology in Severe MAS ```mermaid flowchart TD A[Meconium aspiration]:::outcome --> B[Mechanical obstruction + chemical pneumonitis]:::outcome B --> C[Surfactant inactivation]:::outcome C --> D[Severe ventilation-perfusion mismatch]:::outcome D --> E[Refractory hypoxemia]:::urgent E --> F[Pulmonary vasoconstriction]:::outcome F --> G[Pulmonary hypertension + right-to-left shunting]:::urgent G --> H{Escalate therapy}:::decision H -->|First| I[Surfactant + iNO]:::action H -->|If fails| J[HFOV]:::action H -->|Refractory| K[Consider ECMO]:::urgent ``` ### Stepwise Escalation of Therapy for Severe MAS | Step | Intervention | Rationale | |------|--------------|----------| | **1** | Exogenous surfactant | Restores surfactant inactivated by meconium; improves lung compliance | | **2** | Inhaled nitric oxide (iNO) | Selective pulmonary vasodilator; reduces PH and right-to-left shunting | | **3** | High-frequency oscillatory ventilation (HFOV) | If conventional ventilation fails; reduces ventilator-induced lung injury | | **4** | ECMO | Last resort for refractory hypoxemia despite all above measures | **Key Point:** Surfactant therapy is **evidence-based** in severe MAS. Multiple RCTs show improved oxygenation and reduced need for ECMO. Dosing: 100–200 mg/kg (e.g., poractant alfa 2.5 mL/kg). **High-Yield:** Inhaled nitric oxide (iNO) is **specifically indicated** for neonates with respiratory failure and pulmonary hypertension. Starting dose: 20 ppm. It selectively dilates pulmonary vasculature without systemic hypotension, reducing right-to-left shunting and improving oxygenation. **Clinical Pearl:** The combination of **surfactant + iNO** is synergistic in severe MAS. Surfactant improves ventilation-perfusion matching; iNO reduces pulmonary vascular resistance. This combination resolves 70–80% of severe MAS cases without need for ECMO. **Mnemonic:** **SHINE** — **S**urfactant, **H**igh-frequency ventilation, **I**nhaled **N**itric oxide, **E**CMO (escalation ladder for severe MAS). ### Why NOT Other Options? - **Increasing conventional ventilation parameters alone** risks barotrauma and volutrauma without addressing the underlying pulmonary hypertension. - **Immediate ECMO** is premature before exhausting medical therapy (surfactant, iNO, HFOV). - **Bronchoscopic suction** has **no role** in MAS management — meconium is already in the distal airways and alveoli; suctioning causes further inflammation.